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Introduction
Insulin resistance is associated with a state of low-grade, chronic inflammation with increased expression of proinflammatory mediators, cytokines and chemokines in white adipose tissue (WAT) (Hotamisligil et al., 1995; Kern et al., 1995) . Consistent with this observation, high blood levels of proinflammatory cytokines (e.g. TNFα, and C-reactive protein have been reported in diabetic and insulin resistant subjects (Shoelson et al., 2007) . The proinflammatory responses initiated by these proteins occur primarily through the c-Jun NH 2 -terminal kinase (JNK)/activator protein 1 (AP1) and the IκB kinase (IKK)/NF-κB signaling pathways (Schenk et al., 2008) . Accordingly, the signaling activities of both JNK and IKK are elevated in skeletal muscle from insulin resistant humans and mice, thereby leading to chronic activation of the AP1 and NF-κB pathways with the consequent expression of proinflammatory genes (Yuan et al., 2001; Hirosumi et al., 2002; Cai et al., 2005) . In mice, genetic ablation (KO models) or inhibition of JNK1 or IKKβ results in improved insulin sensitivity in vivo and in vitro (Yuan et al., 2001; Hirosumi et al., 2002; Arkan et al., 2005; Cai et al., 2005; Solinas et al., 2007) . In humans, treatment with salicylates (Salsalate), which inhibit the IKKβ/NF-κB axis, results in improved glucose and lipid homeostasis (Goldfine et al., 2008) . Thus, chronic activation of these proinflammatory pathways is associated with and contributes to the pathogenesis of obesity-related insulin resistance and their pharmacological modulation appears to produce therapeutic benefit to enhance insulin sensitivity.
Recent studies have shown that WAT from obese animals or humans is heavily infiltrated with macrophages that express most of the detectable proinflammatory JPET #161182 molecules, suggesting that they play an important role in insulin resistance and obesityrelated inflammation (Weisberg et al., 2003; Xu et al., 2003) . Mice in which IKKβ or JNK1 genes have been disrupted specifically in the myeloid lineage (which includes macrophages) exhibit increased insulin sensitivity and they are protected from high fat diet-induced glucose intolerance (Arkan et al., 2005; Solinas et al., 2007) . Since the major proinflammatory JNK1/ or IKKβ/NF-κB axis is disabled within macrophages in these animal models, the resulting insulin sensitive phenotype suggests an important contribution of the macrophage NF-κB pathway to inflammation-induced insulin resistance (Arkan et al., 2005) . Accordingly, insulin sensitizers of the thiazolidinedione (TZD) class that act through PPARγ are known to attenuate production of inflammatory mediators that promote insulin resistance (Ricote et al., 1998) . Moreover, mice deficient in macrophage-specific PPARγ exhibit significant glucose intolerance with systemic insulin resistance and respond only partially to TZD treatment Pascual et al., 2007) .
A major potential contributor to macrophage recruitment into WAT during obesity is the soluble mediator monocyte chemoattractant protein-1 (MCP-1), which can be produced by adipocytes, macrophages and other cells (Charo and Taubman, 2004) .
Importantly, MCP-1 is an NF-κB target gene that is expressed at high levels in WAT from obese mice and humans (Sartipy and Loskutoff, 2003; Charo and Taubman, 2004; Bruun et al., 2005) . Studies with adipocytes in vitro indicate that MCP-1 inhibits insulinstimulated glucose uptake, inducing an "insulin-resistant" state in cultured cells (Sartipy and Loskutoff, 2003) . Moreover, genetic deficiency of the MCP-1 receptor CCR2 JPET #161182 6 reduces food intake, delays development of obesity and is accompanied by decreased number of macrophages in WAT, while enhancing systemic glucose homeostasis and insulin sensitivity (Weisberg et al., 2006) . Thus, it appears that adipocyte-derived MCP-1 plays a major role in promoting macrophage recruitment and inflammation in the insulin resistant state.
We have examined a chemically modified version of a naturally occurring 7β-hydroxylated metabolite of Δ 5 -androstenediol, which in turn is derived from dehydroepiandrosterone (DHEA). We refer to the resulting compound as HE3286 (Δ 5 -androstene-17α-ethynyl-3β,7β,17β-triol) , which is metabolically stable (Auci et al., 2009) . Although the precise pharmacological role of DHEA is still controversial, its administration is associated with multiple therapeutic effects when administered to rodents at high doses (Coleman et al., 1984) . This diversity of biological actions may reflect the well-known extensive metabolic biotransformation of DHEA in rodents, from which discrete steroidal metabolites possessing intrinsic and distinct biological activities are generated. In this light, DHEA may act as a prohormone or metabolic precursor of biologically active hormonal effectors (Leiter et al., 1987; Marwah et al., 2002) .
Although DHEA has been shown to improve insulin resistance and glucose homeostasis in diverse animal models of metabolic disease, it has not been possible to demonstrate similar activities in human studies (Nair et al., 2006) . It is thought that the lack of efficacy in humans may reflect large species-specific differences in metabolic transformation of DHEA and limited oral bioavailability (Auci et al., 2009 (Dheda et al., 2004) . PCR primers used were as follows: and a control (Livak and Schmittgen, 2001) . Results were expressed as a ratio in comparison to the reference gene (Pfaffl, 2001 ).
Immunostaining procedures. RAW264.7 macrophages were cultured on glass coverslips and treated with 100 nM HE3286 or vehicle (0.1% DMSO) for 1 hr, followed by 100 ng/mL LPS for 15 minutes. Cells were fixed with 4% paraformaldehyde in PBS, washed, and permeabilized in 0.1% Triton X-100 (Sigma). Cells were washed again and blocked with 1% normal goat serum (Santa Cruz, Santa Cruz, CA) for 1 hr, followed by addition of an anti-NF-κB/p65 monoclonal antibody (IgG1; Santa Cruz) and stained with Immunoblot analysis. Murine intraperitoneal (IP) macrophages were elicited by thioglycolate and isolated as described (Welch et al., 2003) . Briefly, cells were seeded in 6-well plates (7 x 10 6 /10-cm plate) and maintained in DMEM with 15 mM glucose and 10% FBS for three days. Media was changed every 24 hr and cells were then serum- Reference ligands used for each receptor are indicated in Table 1 . transfected with a synthetic plasmid containing three copies of an estrogen response element (ERE) fused upstream of a luciferase gene was used (Wilson et al., 2004) .
Briefly, cells were plated at 20,000 cells/well/100 μL in 96-well clear bottom white assay microtiter plates (Costar) and kept in phenol red-free RPMI supplemented with 4 mM Lglutamine and 10% charcoal-stripped FBS (CHAR-DEX; InVitrogen). Cells were exposed to the various compound dilutions as needed and following an overnight incubation at 37°C, media was aspirated, cells were lysed and luciferase activity was then determined. In some cases, transactivation of ERβ and GR was also performed by transient transfection of HEK293 fibroblasts using expression plasmids encoding fulllength human GR or ERβ and appropriate luciferase reporter vectors (see below). For transactivation activity of the human peroxisome proliferator-activated receptors PPARγ, PPARδ and PPARα, the fluorimetric Gene Blazer ® β-lactamase assay system (InVitrogen) was used following the manufacturer's instructions. Assays were conducted on 384-well plates using a fluorogenic substrate (CCF4-AM, InVitrogen Figure 1A ). In the second study with younger (6-wk old), "pre-diabetic" db/db mice, HE3286 (20 or 40 mg/kg BID) maintained blood glucose levels below 200 mg/dL at all times, comparable to lean db/+ control animals ( Figure 1C ; P<0.001 vs. vehicle).
As expected, animals treated with rosiglitazone (25 mg/kg BID) showed normal glucose levels throughout the study ( Figure 1C ). In contrast, vehicle-treated mice became hyperglycemic with glucose levels exceeding 450 mg/dL after 32 days. These glucose lowering effects occurred in the absence of significant changes in body weight as its rate of accretion was virtually the same among all groups in both studies ( Figures 1B and 1D ).
In addition, oral glucose tolerance tests indicated that HE3286, like rosiglitazone, markedly enhanced glucose clearance in db/db mice after 14 days (P<0.05) or 28 days (P<0.01) of treatment (Figures 2A and 2B ). To determine if these effects may have resulted from amelioration of insulin resistance, serum insulin levels were also measured ( Figure 2C ). Treatment with HE3286 for 4 weeks, like rosiglitazone, caused a significant reduction in insulin levels compared to vehicle (P<0.01-0.001).
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Therefore, the effect of HE3286 on two insulin resistant, non-diabetic models, namely diet-induced obese (DIO) C57BL/6J mice, as well as genetically obese B6.V-Lep ob /J (ob/ob) mice was examined. As shown in Figure 3A and 3B, treatment of DIO-mice with HE3286 significantly enhanced glucose clearance (P<0.05-0.001). Moreover, a reduction of basal blood glucose levels was already apparent in the HE3286-treated mice prior to gavaging the glucose load (see Figure 3A , time 0). OGTT studies indicated that treatment of ob/ob mice with HE3286 significantly improved (P<0.05-0.001) glucose intolerance, in a similar fashion as rosiglitazone ( Figure 3C and 3D), and also markedly reduced serum insulin levels (see below).
Association of anti-inflammatory activity of HE3286 with reduced insulin resistance.
Given the link between insulin resistance and MCP-1-induced macrophage infiltration and inflammation in adipose tissue (Sartipy and Loskutoff, 2003; Weisberg et al., 2006) , it was of interest to assess parallel changes that might occur in the expression of MCP-1 and its receptor CCR2. Expression of mRNA levels of MCP-1 and CCR2 in adipose tissue of diabetic db/db mice receiving vehicle only was markedly increased relative to non-diabetic lean db/+ littermates ( Figure 4A ). However, MCP-1 and CCR2 expression was significantly reduced in db/db mice treated with HE3286 or rosiglitazone (P<0.05)
relative to vehicle-treated animals ( Figure 4A ). This HE3286-induced inhibition of MCP-1 expression in adipose tissue was accompanied by reduced serum levels of MCP-1
This article has not been copyedited and formatted. The final version may differ from this version. Figure 4B ). The anti-inflammatory activity of HE3286 was also evident in obese insulin-resistant ob/ob mice treated with HE3286, in which serum MCP-1 protein levels decreased (P<0.01; Figure 5A ). In addition, the marked increase in serum insulin levels observed in obese ob/ob mice relative to lean ob/+ mice was significantly abrogated in animals treated with HE3286 (P<0.05) but not with vehicle ( Figure 5B ), suggesting that insulin resistance was ameliorated. These effects were accompanied by markedly reduced expression of MCP-1 mRNA expression (P<0.05) in white adipose tissue ( Figure 5C ). Thus, amelioration of insulin resistance and improved glucose utilization by HE3286 treatment is associated with decreased MCP-1 production in white adipose tissue. promoter/reporter constructs. Prior treatment of RAW264.7 cells with HE3286 decreased subsequent activation of NF-κB-driven reporter gene expression in response to LPS stimulation by 50-60% ( Figure 6C ). As expected, NF-κB-dependent luciferase expression was also inhibited by dexamethasone or the MAP kinase inhibitor PD98059.
Taken together, these observations indicate that HE3286 limits activation of NF-κB in macrophages in response to LPS, and suggest that this anti-inflammatory action may contribute to the observed amelioration of glucose intolerance in vivo.
Suppression of proinflammatory signaling kinase cascades. To gain further insight
into the mechanism for the observed anti-inflammatory activity of HE3286, the impact of the compound on major proinflammatory kinase cascades engaged by endotoxin stimulation was studied in RAW264.7 macrophages. As expected, stimulation with LPS led to increased phosphorylation of IKK and NF-κB/p65 (see Figure 6B ), as well as two major pro-inflammatory MAP kinase signaling cascades, namely c-Jun NH 2 -terminal kinase (JNK) and p38 ( Figure 7 ). However, prior exposure to HE3286 resulted in marked suppression in the extent of LPS-induced phosphorylation of these proteins (P<0.05 for all kinases and NF-κB/p65 at least after 60 min of LPS stimulation; Figure   7 ). Although it was not possible to distinguish between IKKα and IKKβ in these experiments given the specificity of the antibodies used (phospho-IKKα/β-Ser 180/181), it is of interest to note that IKKβ has been implicated in downregulation of insulin receptor substrate-1 (IRS-1) signaling through increased phosphorylation on serine residues (Arkan et al., 2005) . These findings suggest that HE3286 causes a broad antiinflammatory effect characterized by impaired LPS-induced upstream activation of IKK This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
In this report, we have studied the novel, synthetic compound HE3286, a 17α-ethynyl-substituted analogue of the naturally occurring DHEA metabolite Δ 5 -androstene-3β,7β,17β-triol (Marwah et al., 2002) and show that HE3286 improves glucose metabolism and exhibits antidiabetic effects. Thus, when orally administered to diabetic db/db mice twice-a-day for 4 weeks, HE3286 delays progression to hyperglycemia in the absence of any significant changes in body weight. Treatment with HE3286 also led to markedly enhanced glucose tolerance in diabetic db/db mice, insulin resistant dietinduced (DIO) mice and in genetically obese ob/ob mice. These effects were accompanied by decreased hyperinsulinemia and reduced expression levels of MCP-1 mRNA in WAT, which is consistent with diminished serum levels of MCP-1 as well.
Likewise, reduced mRNA expression of the MCP-1 receptor CCR2 in WAT from db/db mice was observed. These results indicate that, in addition to ameliorating glucose intolerance and insulin resistance, HE3286 possesses anti-inflammatory properties that act to abrogate excessive MCP-1 production in WAT 1 .
Since the MCP-1 pathway is known to play a role in recruiting macrophages into adipose tissue and in the development of obesity-related insulin resistance (Xu et al., 2003; Bruun et al., 2005; Weisberg et al., 2006) , it is possible that the HE3286-induced improvement in glucose metabolism is, at least in part, a result of anti-inflammatory promoter/enhancer develop insulin resistance and hepatic steatosis, whereas an insulin sensitive phenotype is observed in homozygous MCP-1 KO mice or in animals in which 7ND, a dominant-negative mutant of MCP-1, is acutely expressed after injection of an expression plasmid (Kanda et al., 2006) . Furthermore, treatment of DIO-C57BL/6J mice with INCB3344, a selective CCR2 antagonist (Brodmerkel et al., 2005) , results in enhanced glucose disposal and insulin sensitivity (Weisberg et al., 2006) . Therefore, it seems reasonable to suggest that a drug that attenuates expression and production of MCP-1 can have therapeutic benefit, possibly as a result of diminished macrophage infiltration into WAT with attendant improved glucose homeostasis and increased insulin sensitivity.
The ability of HE3286 to inhibit MCP-1 expression appears to result from broader anti-inflammatory actions as indicated by our results on NF-κB function in macrophages.
We found that LPS-induced nuclear translocation of NF-κB was inhibited by HE3286 in cultured RAW264.7 mouse macrophages. HE3286 also caused inhibition of NF-κB-dependent reporter gene expression, as well as a decrease in LPS-induced p65 phosphorylation. These three observations strengthen the conclusion that HE3286
attenuates NF-κB function in macrophages, leading to reduced MCP-1 gene expression.
On the other hand, attenuation of NF-κB function per se could translate into therapeutic effects on glucose metabolism. Other reports have shown that inhibition of NF-κB by adenoviral-mediated expression of the IκBα superrepressor SR-IκBα prevents insulin resistance in cultured hepatocytes in vitro (Iimuro et al., 1998) and improves hepatic insulin action and glucose homeostasis in db/db mice in vivo (Tamura et al., 2007) . These studies provide strong support to the notion that inhibition of NF-κB activity in diabetes/insulin resistance can improve disordered glucose homeostasis.
Although HE3286 inhibits activation and function of NF-κB in LPS-stimulated macrophages, the basis for this inhibition appears to reside upstream of NF-κB activation.
Thus, prior exposure of macrophages to HE3286 resulted in suppression of LPS-induced activation of the IKK/NF-κB axis, as well as two major pro-inflammatory MAP kinase pathways (JNK and p38). In macrophages, these kinase signaling cascades are typically activated by pattern-recognition Toll-like receptors, of which TLR4 is the major target of LPS (Medzhitov, 2001 ). Since it has been shown that TLR4 can transduce the proinflammatory signals of fatty acids (Shi et al., 2006) , which are often elevated in insulin resistant states, it is tempting to speculate that HE3286 might interfere with TLR4 function, leading to suppression of proinflammatory cascades.
Despite the structure of HE3286, which defines it as a C-19 Δ 5 -androstene species different from glucocorticoids, we tested its ability to bind or transactivate GR and found a lack of activity (see Table 2 ). Similarly, HE3286 does not exhibit any detectable In contrast to TZD-based insulin sensitizers that target PPARγ, HE3286 did not induce PPARγ-mediated transactivation activity compared to rosiglitazone or GW1929 (see Fig. 7 ). This is an important pathway to explore since it is likely that at least part of the insulin sensitizing effects of TZDs involve PPARγ-mediated anti-inflammatory responses due to transrepression of inflammatory mediators (Ricote et al., 1998; Welch et al., 2003) . Moreover, deletion of the PPARγ gene from macrophages results in impaired glucose tolerance, insulin resistance and increased expression of inflammatory effectors, indicating that macrophage PPARγ is required for the full insulin sensitizing effects of TZDs . The fact that HE3286 fails to transactivate PPARγ suggests that its anti-inflammatory and antidiabetic effects occur through a PPARγ-independent pathway.
Although GR, ER and PPAR receptors are important in metabolic regulation and inflammation, there are certain nuclear receptor subtypes which also play an important role in these functions. For example, the liver X receptors LXRα and β serve as oxysterol sensors that can suppress hepatic gluconeogenesis and attenuate NF-κB function through transrepression mechanisms (Bensinger and Tontonoz, 2008) . Similarly, the retinoic acid receptor-related orphan receptor RORα is a key modulator of lipid homeostasis that can increase fatty acid oxidation in skeletal muscle (Lau et al., 2004) , and can also suppress inflammation and NF-κB function (Delerive et al., 2001 ).
Thus, it is clear that additional work will be necessary to assess the possibility that the beneficial effects of HE3286 might also reflect modulation of non-classic nuclear receptors.
A major drawback of efficacy studies in rodent models of metabolic disease is the possibility that the pharmacological activity of a new drug may fail to translate in humans. In the particular case of HE3286, we believe that this concern is diminished in light of emerging clinical data in obese, insulin resistant human subjects, in whom daily treatment with HE3286 for 4 weeks is associated with improved whole body insulin sensitivity as determined by glucose clamp studies (work in progress). In these studies, it will be important to continue to explore the underlying hypothesis of the link between inflammation and insulin resistance by determining whether the beneficial effects of HE3286 on glucose homeostasis are associated with anti-inflammatory activity.
Furthermore, completion of phase II clinical trials with HE3286 in type 2 diabetic subjects currently in progress should provide additional support for the potential translation of the therapeutic effects described here to long-term glycemic control.
In summary, the current studies demonstrate the antidiabetic and antiinflammatory properties of HE3286, a synthetic analogue of a naturally occurring Δ macrophages transiently transfected with an NF-κB/luciferase reporter vector were left untreated (basal) or exposed to 1, 10 and 100 nM HE3286, 10 nM PD98059 or 10 nM dexamethasone for 1 hr, followed by stimulation with 100 ng/mL LPS for 6 hr. The resulting activation of NF-κB was assessed by luciferase activity in cell lysates. Data shown as mean ± SEM and normalized with respect to LPS-treated cells. These cells endogenously express both AR and GR (Wilson et al., 2002) . e T47D-kBluc -Cells stably transfected with an estrogen-sensitive synthetic promoter/reporter construct (ERE) fused upstream of a luciferase gene. These cells express endogenously both ERα and ERβ (Wilson et al., 2004) . 
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